Security Snapshot

X4 Pharmaceuticals, Inc - Common Stock (XFOR) Institutional Ownership

CUSIP: 98420X202

13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

75

Shares (Excl. Options)

85,919,846

Price

$4.00

Type / Class
Equity / Common Stock
Symbol
XFOR on Nasdaq
Shares outstanding
87,101,353
Price per share
$4.24
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
85,919,846
Total reported value
$343,681,474
% of total 13F portfolios
0%
Share change
+57,015,275
Value change
+$228,817,038
Number of holders
75
Price from insider filings
$4.24
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • XFOR - X4 Pharmaceuticals, Inc - Common Stock is tracked under CUSIP 98420X202.
  • 75 institutions reported positions in Q4 2025.
  • 12 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 75 to 2 between Q4 2025 and Q1 2026.
  • Reported value moved from $343,681,474 to $9,683.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 98420X202?
CUSIP 98420X202 identifies XFOR - X4 Pharmaceuticals, Inc - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of X4 Pharmaceuticals, Inc - Common Stock (XFOR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Empery Asset Management, LP 10% 0% $35,180,748 +$25,462,897 9,043,894 +262% Empery Asset Management, LP 31 Dec 2025
MORGAN STANLEY 10% +8.9% $29,940,219 +$2,318,051 8,884,338 +8.4% Morgan Stanley 28 Feb 2026
FMR LLC 9.7% $33,996,400 8,499,100 FMR LLC 31 Oct 2025
Saturn V Capital Management LP 7.4% $25,026,241 6,433,481 Saturn V Capital Management LP 24 Oct 2025
PERCEPTIVE ADVISORS LLC 7.6% $20,980,760 6,064,680 Perceptive Advisors LLC 27 Oct 2025
Trails Edge Capital Partners, LP 5.8% -41% $20,333,894 +$11,320,168 5,227,222 +126% Trails Edge Capital Partners, LP 31 Dec 2025
Growth Equity Opportunities 18 VGE, LLC 6.2% -38% $17,496,802 +$9,734,867 5,057,610 +125% Growth Equity Opportunities 18 VGE, LLC 27 Oct 2025
BIOTECHNOLOGY VALUE FUND L P 3.9% -60% $13,272,653 +$4,544,819 3,411,993 +52% BVF PARTNERS L P/IL 31 Dec 2025
Coastlands Capital LP 10% 0% $7,773,911 +$37,418 2,491,638 +0.48% Coastlands Capital LP 03 Oct 2025
Nantahala Capital Management, LLC 2.8% -72% $9,528,431 +$798,030 2,449,468 +9.1% Nantahala Capital Management, LLC 31 Dec 2025
Deep Track Capital, LP 10% $4,568,300 2,366,995 Deep Track Capital, LP 12 Aug 2025
BlackRock, Inc. 3% $377,954 179,125 BlackRock, Inc. 30 Jun 2025

As of 31 Dec 2025, 75 institutional investors reported holding 85,919,846 shares of X4 Pharmaceuticals, Inc - Common Stock (XFOR). This represents 99% of the company’s total 87,101,353 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) together control 96% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Empery Asset Management, LP 10% 8,951,105 0% 32% $35,804,420
FMR LLC 9.8% 8,499,100 0% $33,996,400
MORGAN STANLEY 9.4% 8,208,015 +220072% 0% $32,832,060
Bain Capital Life Sciences Investors, LLC 9.1% 7,967,454 +227% 2.4% $31,869,816
PERCEPTIVE ADVISORS LLC 7.2% 6,314,452 0.46% $25,257,808
Saturn V Capital Management LP 6.7% 5,800,530 4.3% $23,202,120
Deep Track Capital, LP 5.8% 5,013,661 +347% 0.46% $20,054,644
Kalehua Capital Management LLC 4.3% 3,722,840 0% 15% $14,891,360
VANGUARD GROUP INC 3.9% 3,423,662 +734% 0% $13,694,648
BRAIDWELL LP 3.9% 3,368,904 0.43% $13,475,616
Blackstone Inc. 3.1% 2,681,922 0.05% $10,727,688
Rosalind Advisors, Inc. 3% 2,605,920 +69% 4% $10,423,680
Trails Edge Capital Partners, LP 3% 2,571,478 0% 2.5% $10,285,912
Nantahala Capital Management, LLC 2.8% 2,449,468 +9.9% 0.58% $9,797,872
BVF INC/IL 2.6% 2,233,742 0% 0.3% $8,934,968
SAMSARA BIOCAPITAL, LLC 2.3% 1,960,000 0.81% $7,840,000
Siren, L.L.C. 1.7% 1,500,000 0.18% $6,000,000
BlackRock, Inc. 1.4% 1,226,808 +1881% 0% $4,907,232
Woodline Partners LP 1.1% 1,000,855 0.02% $4,003,420
GEODE CAPITAL MANAGEMENT, LLC 1.1% 940,447 +1081% 0% $3,763,835
STEMPOINT CAPITAL LP 1% 898,465 +62% 0.62% $3,593,860
GOLDMAN SACHS GROUP INC 0.96% 831,890 0% $3,327,560
Point72 Asset Management, L.P. 0.93% 808,154 +3630% 0.01% $3,232,616
Stonepine Capital Management, LLC 0.68% 593,573 -44% 1.9% $2,374,292
SILVERARC CAPITAL MANAGEMENT, LLC 0.41% 357,387 0.21% $1,429,548

Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 2,327 $9,683 -$3,130 $4.24 2
2025 Q4 85,919,846 $343,681,474 +$228,817,038 $4.00 75
2025 Q3 13,652,105 $46,690,414 +$40,048,768 $3.42 40
2025 Q2 2,150,633 $4,086,190 +$4,064,925 $1.90 49
2025 Q1 83,045 $20,007 +$20,007 $0.24 2

Sponsored